RestoreVision

Biotech · Tokyo, JP

Develops RV-001, an optogenetic gene therapy (chimeric rhodopsin via AAV) to restore vision in retinal diseases.

In the network

Shares the most investors with (number = shared investors):

Create a free EquityFlow account to see RestoreVision's 1 funding round, 9 investors, 12 similar companies.